Altered lipid metabolism in ADPKD patients treated with Tolvaptan

被引：0
|
作者：
Bargagli, Matteo [1 ]
Anderegg, Manuel [2 ]
Huynh-Do, Uyen [2 ]
Vogt, Bruno [2 ]
Ferraro, Pietro Manuel [3 ]
Fuster, Daniel [2 ]
机构：
[1] Univ Bern, Bern Univ Hosp, Dept Hypertens & Nephrol, Inselspital, Bern, Switzerland
[2] Univ Bern, Bern Univ Hosp, Dept Nephrol & Hypertens, Inselspital, Freiburgstr 75, CH-3070 Bern, Switzerland
[3] Fdn Policlin Univ A Gemelli IRCCS, UOS Terapia Conservat Malattia Renate Cronica, LA Gemelli 8, I-00768 Rome, Italy
来源：
SWISS MEDICAL WEEKLY | 2022年 / 152卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OC 32 / P
引用
收藏
页码：16S / 16S
页数：1
相关论文
共 50 条
  • [11] Tolvaptan in ADPKD Patients With Very Low Kidney Function
    Torres, Vicente E.
    Gansevoort, Ron T.
    Perrone, Ronald D.
    Chapman, Arlene B.
    Ouyang, John
    Lee, Jennifer
    Japes, Hina
    Nourbakhsh, Ali
    Wang, Tao
    KIDNEY INTERNATIONAL REPORTS, 2021, 6 (08): : 2171 - 2178
  • [12] ADPKD, Tolvaptan, and Nephrolithiasis Risk
    Hoorn, Ewout J.
    Zietse, Robert
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 15 (07): : 923 - 925
  • [13] Long-term efficacy of tolvaptan therapy in patients with ADPKD
    Geertsema, Paul
    Bais, Thomas
    Kuiken, Vera
    Knol, Martine
    Casteleijn, Niek F.
    Vart, Priya
    Meijer, Esther
    Gansevoort, Ronald
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [14] Quality of Life and Tolerability of Jinarc® (Tolvaptan) in Swiss ADPKD Patients
    Anderegg, Manuel
    Dhayat, Nasser
    Semmo, Mariam
    Huynh-Do, Uyen
    Vogt, Bruno
    Fuster, Daniel
    SWISS MEDICAL WEEKLY, 2018, 148 : 6S - 6S
  • [15] Long-term efficacy of tolvaptan therapy in patients with ADPKD
    Geertsema, Paul
    Bais, Thomas
    Kuiken, Vera
    Knol, Martine
    Casteleijn, Niek F.
    Vart, Priya
    Meijer, Esther
    Gansevoort, Ronald
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I421 - I421
  • [16] IMPLEMENTING A VIRTUAL NEPHROLOGY PANEL FOR TOLVAPTAN USE IN PATIENTS WITH ADPKD
    Lin Duong
    Taneja, Nidhika
    Belani, Sharina
    Irannejad, Pardis
    Jain, Anagha
    Lieberman, Jonathan
    Tuan Nguyen
    Ramaswamy, Deepa
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2021, 77 (04) : 590 - 590
  • [17] ALTERED LIPID-METABOLISM IN PMA-TREATED MYOBLASTS
    GROVE, RI
    MANGINI, M
    BOOTHBY, R
    SCHIMMEL, SD
    FEDERATION PROCEEDINGS, 1980, 39 (06) : 2187 - 2187
  • [18] ADAPTING THE ADPKD OUTCOMES MODEL TO PREDICT COST CONSEQUENCE IN ITALIAN PATIENTS WITH AUTOS OMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) TREATED WITH JINARC (TOLVAPTAN)
    Mennini, F. S.
    Marcellusi, A.
    Russo, S.
    Iorio, A.
    Lanati, E. P.
    Robinson, P.
    VALUE IN HEALTH, 2015, 18 (07) : A755 - A755
  • [19] What is the Appropriate Dose of Tolvaptan in ADPKD?
    Dahl, Neera K.
    Torres, Vicente E.
    KIDNEY INTERNATIONAL REPORTS, 2024, 9 (04): : 737 - 739
  • [20] Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use
    Mizuno, Hiroki
    Sekine, Akinari
    Suwabe, Tatsuya
    Ikuma, Daisuke
    Yamanouchi, Masayuki
    Hasegawa, Eiko
    Sawa, Naoki
    Ubara, Yoshifumi
    Hoshino, Junichi
    PLOS ONE, 2022, 17 (02):
12345